Welcome to our dedicated page for Waldencast plc news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast plc stock.
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform built around the Obagi Medical and Milk Makeup brands. Its news flow centers on segment performance, brand initiatives, and platform-level strategic decisions, providing investors and observers with regular insight into how the company executes its brand-led strategy.
Company updates frequently include quarterly and half-year financial results, furnished to the U.S. Securities and Exchange Commission on Form 6-K and summarized in detailed press releases. These communications break out net revenue, adjusted gross profit, and adjusted EBITDA for Waldencast as a whole and for the Obagi Medical and Milk Makeup segments, highlighting trends across channels and geographies as described by the company.
News related to Obagi Medical often covers product and portfolio developments, clinical data, and expansion into aesthetics. Examples include announcements about FDA approval of Obagi-branded hyaluronic acid injectable products, new clinical data on Obagi hyaluronic acid injectables and scalp serum at professional dermatology meetings, and the acquisition of Novaestiq Corp. and U.S. rights to the Saypha injectable line. These items illustrate how Waldencast presents Obagi Medical’s role at the intersection of skincare and medical aesthetics.
Updates about Milk Makeup focus on brand performance in prestige beauty and digital channels, including references to U.S. retail sales trends, expansion into retailers such as Ulta Beauty and Amazon Premium Beauty, and the impact of specific product launches as described in the company’s quarterly commentary.
At the corporate level, Waldencast’s news also addresses strategic reviews and financing actions, such as the announced review of strategic alternatives by the Board of Directors, the sale of the “Obagi” trademark in Japan, and new credit agreements. Readers of the WALD news page can expect a mix of earnings updates, brand-specific developments, clinical and regulatory milestones, and capital structure announcements directly sourced from company press releases and related SEC filings.
Obagi Medical (NASDAQ: WALD) launched NU-GEN™ Cellular Renewal Serum on March 24, 2026, a 1oz/30ml topical formula priced at $175 that pairs NAD+ with NMN and niacinamide to address nine visible signs of skin aging.
Clinical results cited include up to six years of visible age reversal, 51% improvement in tone evenness, 30% reduction in fine lines, and rapid hydration gains within 30 minutes.
Obagi Medical (NASDAQ: WALD) announced a collaboration with ProMD Health on March 19, 2026 to enroll ProMD’s multi-location network in the ALOHA Program to evaluate Obagi® saypha® MagIQ™ in real-world practice. The program will use standardized data collection across 17 ProMD locations and combine Obagi clinical education with ProMD injector experience to assess clinical efficacy, patient experience, and integrated post-care protocols, contributing to growing real-world evidence for MagIQ’s performance in diverse aesthetic settings.
Waldencast (NASDAQ: WALD) reported FY2025 net revenue of $272.1M (flat YoY) and Q4 2025 net revenue of $72.0M. Adjusted EBITDA was $16.1M for FY2025 and $6.6M for Q4. The company completed the sale of Obagi Japan for $82.5M and refinanced with a $225M three-year credit facility, lowering net debt to $121.7M.
Obagi Medical grew, including FDA approval and acquisition activity tied to injectables; Milk Makeup saw U.S. gains but softer international sales.
Waldencast (NASDAQ: WALD) said it will release Fourth Quarter and Fiscal Year 2025 results on March 13, 2026 before U.S. market open. The company also said it will not host a conference call to discuss results due to its ongoing strategic review.
Obagi Medical (NASDAQ: WALD) announced a collaboration with Schweiger Dermatology to run the ALOHA Program, launching a Phase 4 clinical study and a real-world evaluation to generate post‑approval evidence for Obagi® saypha® MagIQ™. Initial activities are expected to begin in early 2026.
The program aims to translate pivotal trial safety and efficacy into everyday practice across Schweiger’s national network and present findings internally and at industry conferences.
Obagi Medical (NASDAQ: WALD) announced a collaboration with It’s a Secret Med Spa on Feb 25, 2026 to enroll premium med spa locations in the ALOHA real-world program evaluating saypha® MagIQ™. The program will capture standardized real-world data across participating sites and integrate Obagi protocols.
It’s a Secret brings 15 high-end locations and luxury clinical experience to support evaluation and patient outcomes.
Obagi Medical (NASDAQ: WALD) announced a collaboration with Aesthetic Record to run the ALOHA Real-World Program for Obagi® saypha® MagIQ™, aiming to translate FDA pivotal trial results into everyday practice across multiple providers.
The program leverages Aesthetic Record’s EMR platform used by over 9,000 clinics to capture standardized clinical data, run structured evaluations, and present initial findings at industry conferences.
Obagi Medical (NASDAQ: WALD) announced a collaboration with DermFx to run the ALOHA Real-World Program for Obagi® saypha® MagIQ™, aiming to translate FDA pivotal trial results into routine med spa practice. The program will use standardized data capture across DermFx’s five Southern California locations and present initial findings internally.
The partnership emphasizes evidence-based rollout, provider training, integrated skincare-injectable protocols, and support for regional practices to evaluate patient outcomes and satisfaction.
Obagi Medical (NASDAQ: WALD) announced a strategic collaboration with Moxie to run the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program, a real-world evidence initiative evaluating saypha MagIQ across Moxie-supported aesthetic practices. Standardized data collection and early results will be shared at industry events.
Obagi Medical (NASDAQ: WALD) launched a two-step Lip Therapy protocol on February 3, 2026: Lip Therapy AHA + PHA Smoothing Micro-Peel ($55) and Soothe & Protect Lip Treatment SPF 30 ($40). The regimen pairs nightly chemical resurfacing with daily hydration and SPF to improve texture, hydration, and fine lines.
Products are available through professional channels now and on Obagi.com beginning February 3, 2026. Consumer perception testing reported immediate and two-week improvements in hydration and appearance.